Praluent is the first and only PCSK9 inhibitor approved in the U.S. and is available in two different doses (75 mg and 150 mg). Both doses of Praluent are available in a single 1 milliliter (mL) ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary ...
Dear Dr. Roach: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
TARRYTOWN, Regeneron Pharmaceuticals, Inc. Sanofi today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the ...
DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback